Project Grant R35GM155282

Award Date 7/15/24
Completion Date 5/31/29
Dollars Obligated $1.2M
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Durham, NC 27708, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $202,274 to develop an easy-to-use computer program for predicting the structure and degrading efficiency of proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional molecules that induce the degradation of target proteins by recruiting them to E3 ubiquitin ligases. The awarded project aims to implement a...
The National Institute of General Medical Sciences (NIGMS) awarded a $298,530 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Epigenter, LLC in Providence, RI. The goal of this 1-year award, effective July 1, 2025, is to develop and characterize "self-delivering" epigenetic editor proteins that can modulate gene expression by targeted DNA demethylation, without requiring genetic transduction. The project will compare two different protein...
This Project Grant from the National Institutes of Health's Trans-NIH Research Support program, totaling $2,844,000, will support the development of new chemical tools for selectively manipulating aggregate proteostasis in cells and in vivo using a targeted protein degradation approach. Funded from September 2022 through August 2025, the University of California, San Diego will apply technologies and concepts from targeted protein degradation cancer therapy research to central challenges in...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of engineered enzymes that can be activated to perform targeted modifications of cellular proteins. The $1,602,000 award to the Dana-Farber Cancer Institute, Inc. (DFCI) will fund research to design and apply novel autoinhibited enzymes that can toggle between inactive and active conformations in response...
This three-year, $2.8 million Project Grant from the Department of Health and Human Services' Biomedical Research and Research Training program will fund the development of new methods for post-translational modification proteomics with spatial and temporal resolution. The University of Wisconsin-Madison, in collaboration with the University of Wisconsin System, will engineer genetically targetable enzymes to tag post-translationally modified proteins in specific subcellular locations. This will...
This $584,420 Project Grant, awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports research into spatiotemporal mapping and engineering of the "dark proteome" - intrinsically disordered proteins and their functions. The principal objectives of the grant are to: (1) investigate the role of protein disorder in facilitating transport through the nuclear pore complex, including developing...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $124,767 to The Regents of the University of California, San Francisco (UCSF) to develop and test a pipeline for the de novo design of protein "enfolds" that can conditionally release cell-penetrating peptides (CPPs) and antimicrobial peptides (AMPs). The goal is to enhance the tissue specificity and stability of...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $275,000 to Ubiquitx Inc., a New York-based small business, to develop a programmable, modular therapeutic platform for the direct modification of proteins of interest (POIs) using artificial intelligence, protein engineering, and mRNA therapeutics. The goal is to expand the applications of the company's Chimeric Ligands for Induced Proximity (CLIPS)...
This Project Grant award of $388,621 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support the development of novel molecular designs with therapeutic potential. The key objectives are: Developing ligand-heterocycle conjugates as targeted RNA degraders with rapid kinetics and selectivity for cancer-associated G-quadruplexes. Engineering nucleic acid polymers with (thio)phosphoramidate backbones as biostable...
This $328,000 federal Project Grant award, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports the development and application of an RNA editing platform called TRIBE-ID. The platform will be used to investigate dynamic RNA-protein interactions in cells, with the goal of advancing the understanding of RNA regulatory mechanisms and accelerating the development of RNA-targeted therapeutics....

TOWARDS THE DESIGN OF PROGRAMMABLE, ISOFORM-SELECTIVE PROTEOME EDITING SYSTEM - ABSTRACT THE PROPOSED WORK IN THIS MIRA APPLICATION FOCUSES ON MY LONG-TERM GOAL TO CREATE PROGRAMMABLE TOOLKITS FOR PROTEOME EDITING. INSPIRED BY RESEARCH INTO DEVELOPING BROAD-TARGETING CRISPR ENZYMES FOR PROGRAMMABLE GENOME EDITING, MY LABORATORY DESIGNS ANALOGOUS PEPTIDE-GUIDED ENZYMES FOR POST-TRANSLATIONALLY MODIFYING TARGET PROTEINS FROM SEQUENCE ALONE, ENABLING TARGETING OF BOTH STRUCTURALLY-STABLE AND DISORDERED PROTEINS. TO THIS POINT, WE LEVERAGE GENERATIVE ARTIFICIAL INTELLIGENCE APPROACHES TO DESIGN THESE PEPTIDES, INCLUDING PROTEIN LANGUAGE MODEL (PLM)-BASED INTERFACE PREDICTORS AND DIFFUSION MODELS FOR DE NOVO PEPTIDE BINDER GENERATION. INTEGRATED WITH THESE EFFORTS, WE EXPERIMENTALLY ENGINEER PEPTIDE-E3 UBIQUITIN LIGASE FUSIONS (TERMED UBIQUIBODIES OR UABS) THAT CAN DEGRADE DIVERSE PATHOGENIC PROTEINS. BUILDING UPON THIS WORK, WE WILL COMBINE OUR CURRENT TECHNOLOGIES AND EXPAND OUR RESEARCH INTO THREE NEW AREAS TO ENABLE BROAD-SCALE PROTEOME EDITING APPLICATIONS VIA GENERATIVE PROTEIN LANGUAGE MODELING. FIRST, WE WILL BUILD UPON OUR CURRENT EXPERIMENTAL EFFORTS TO ENABLE PEPTIDE-GUIDED DEUBIQUITINATION, THUS ENABLING BOTH PROTEIN DEGRADATION WITH OUR UABS AND NOW PROTEIN STABILIZATION OF TARGET PROTEINS. TO ACCOMPLISH THIS GOAL, WE WILL EXPLORE FUSION OF GENERATED PEPTIDE BINDERS TO DEUBIQUITINASE DOMAINS, AS WELL AS TO DESIGNED RECRUITER DOMAINS OF ENDOGENOUS DEUBIQUITINASES. THE RESULTS OF THIS RESEARCH WILL ESTABLISH EASY-TO-DESIGN "ON" AND "OFF" SWITCHES FOR CONTROLLING PROTEIN STATES IN CELLS. SECOND, WE WILL DEVELOP A NEW LINE OF INVESTIGATION, SPECIFICALLY TO ENABLE MUTANT-SPECIFIC TARGETING OF PROTEIN VARIANTS. HERE, WE WILL LEVERAGE THE VARIANT PREDICTION CAPABILITIES OF STATE-OF-THE-ART PLMS, ALONGSIDE GAUSSIAN PROCESS-BASED PREDICTORS, TO PRIORITIZE BINDERS THAT DISCRIMINATE BETWEEN WILD-TYPE PROTEINS AND HIGHLY-SIMILAR MUTANT VARIANTS THAT CONFER PATHOGENIC PROPERTIES. THESE BINDERS CAN THEN BE INTEGRATED INTO OUR DEGRADATION AND STABILIZATION ARCHITECTURES FOR EXPERIMENTAL VALIDATION. WE ENVISION THAT THIS NEW LINE OF INVESTIGATION WILL ENABLE SELECTIVE DEGRADATION OF MUTANT, DISEASE-CAUSING PROTEINS, SUCH AS MUTANT HUNTINGTIN PROTEIN OR MUTANT KRAS. THIRD, WE WILL ESTABLISH A SPECIFIC FOCUS ON SELECTIVELY TARGETING DYSREGULATED, POST-TRANSLATIONALLY-MODIFIED PROTEINS, WHICH HAVE NUMEROUS IMPLICATIONS IN VARIOUS DISEASES, SUCH AS AGING AND CANCER. TO ENABLE DISCRIMINATION BETWEEN WILD-TYPE PROTEINS AND THEIR MODIFIED COUNTERPARTS, WE WILL TRAIN NEW PTM-SPECIFIC PROTEIN LANGUAGE MODELS VIA BOTH MASKED LANGUAGE MODELING AND AUTOREGRESSIVE TRAINING TASKS. BY INTEGRATING SWISSPROT ANNOTATIONS WITH UNIQUE PER AMINO ACID-BASED TOKENIZATION STRATEGIES, THE RESULTS OF THIS RESEARCH WILL ENABLE THE DESIGN OF DEGRADERS THAT ARE SELECTIVE TO MODIFIED PROTEINS, SUCH AS PHOSPHORYLATED ONCOGENIC DRIVERS, LEAVING WILD-TYPE ISOFORMS INTACT. TOGETHER, THE WORK WE PROPOSE IN THIS MIRA APPLICATION PROMISES TO YIELD ROBUST, SCALABLE, AND MOST IMPORTANTLY, PROGRAMMABLE TOOLS FOR PROTEIN TARGETING AND EDITING APPLICATIONS.

Posted 7/3/24